Epidemiological Surveillance of HIV-1 Transmitted Drug Resistance in Spain in 2004-2012: Relevance of Transmission Clusters in the Propagation of Resistance Mutations.
Geographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance: an individual-patient- and sequence-level meta-analysis.
Result: M46I/L, I85V, and L90M were the four most common PI SDRMs in SSA and SSEA, and among the six most common SDRMs in all regions.
Result: In all regions, the proportion of PI-treated individuals with M46L or I85V divided by the number of ARV-naive individuals with these SDRMs was much lower than the same proportion for all other commonly occurring SDRMs.
Viral Genetic Diversity and Polymorphisms in a Cohort of HIV-1-Infected Patients Eligible for Initiation of Antiretroviral Therapy in Abuja, Nigeria.
PMID: 25582324
2015
AIDS research and human retroviruses
Result: In the PR region, one sample displayed the K43T mutation; another one had the M46L, while a third specimen had K53Y, A71V, and I85V.
Result: The CPR analysis identified the PI mutations M46L, I85V, and F53Y as well as the NRTI mutations M41L and V75M, and the NNRTI mutations K101E, K103N, and G190A as Surveillance Drug Resistance Mutations (SDRM).
Discussion: A rare treatment-associa
HIV-1 drug resistance in the iPrEx preexposure prophylaxis trial.
PMID: 24740633
2014
The Journal of infectious diseases
Result: Viruses from 6 participants (3 FTC/TDF, 3 placebo) had other single nucleoside reverse-transcriptase inhibitor (NRTI; M41L), nonnucleoside reverse-transcriptase inhibitor (NNRTI; K103N/E), or protease inhibitor (PI)-selected (I85V) SDRM (Table 1).
Table: I85V
Persistence of HIV-1 transmitted drug resistance mutations.
PMID: 23904291
2013
The Journal of infectious diseases
Table: I85 V
Emergence of drug resistance-associated mutations in HIV-1 subtype C protease gene in north India.
Abstract: Approximately 70% polymorphisms as minor mutations were observed in protease gene, of which 14 distinct amino acids changes were linked to partial DR such as G16E, K20R, M36I, D60E, I62V, L63P, I64M, H69K, T74A/S, V77I, V82I, I85V, L89M, and I93L.
Low frequency of genotypic resistance in HIV-1-infected patients failing an atazanavir-containing regimen: a clinical cohort study.
PMID: 23711895
2013
The Journal of antimicrobial chemotherapy
Abstract: The minor mutations most strongly associated with atazanavir experience were M36I, M46I, F53L, A71V, V82T and I85V (P < 0.05).
Prevalence of HIV-1 drug resistance among women screening for HIV prevention trials in KwaZulu-Natal, South Africa (MTN-009).
Figure: Histogram showing number of women with drug resistant HIV infection that had each of the following protease inhibitor (PI), nucleoside reverse transcriptase inhibitor (NRTI) or non-nucleoside reverse transcriptase inhibitor (NNRTI) mutations M46L, I85V, K65R, L74I, K219E, M184V, K101E, V106M, Y181C or G190A.
Genetic diversity and drug resistance among newly diagnosed and antiretroviral treatment-naive HIV-infected individuals in western Yunnan: a hot area of viral recombination in China.
Abstract: A total of 1.3% of DR were related to protease inhibitors (PIs), including I85IV, M46I and L90M; 0.3% to nucleoside reverse transcriptase inhibitors (NRTIs), including M184I; and 2.7% to non-nucleoside reverse transcriptase inhibitors (NNRTIs), including K103N/S, Y181C, K101E and G190A.
Result: Although I85V is a nonpolymorphic PI-selected mutation,
Table: I85V
Impact of lopinavir/ritonavir use on antiretroviral resistance in recent clinical practice.
PMID: 22733652
2012
The Journal of antimicrobial chemotherapy
Abstract: Mutations in the protease gene significantly selected between baseline and failure were L10V, K20R, L33F, M36I, I47V, I54V, A71V and I85V (P < 0.05).
HIV mutation literature information.
PMID: 
2015
PloS one
Browser Board
Co-occurred Entities
Filtrator
ViMRT